Kevin Gordon Net Worth

The estimated Net Worth of Kevin K Gordon is at least $833 millier dollars as of 11 December 2023. Mr. Gordon owns over 2,500 units of Progyny Inc stock worth over $225,657 and over the last 21 years he sold PGNY stock worth over $325,849. In addition, he makes $281,940 as Independent Director at Progyny Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Gordon PGNY stock SEC Form 4 insiders trading

Kevin has made over 7 trades of the Progyny Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of PGNY stock worth $89,825 on 11 December 2023.

The largest trade he's ever made was exercising 15,000 units of Progyny Inc stock on 8 June 2022 worth over $110,850. On average, Kevin trades about 1,551 units every 54 days since 2003. As of 11 December 2023 he still owns at least 9,854 units of Progyny Inc stock.

You can see the complete history of Mr. Gordon stock trades at the bottom of the page.

Kevin Gordon biography

Kevin K. Gordon serves as Independent Director of the Company. Mr. Gordon has also served on the board of directors of Veracyte, Inc., a genomic diagnostics company, since December 2016, and Q Holdco Limited, a private company that provides world class engineered and elastomeric solutions, since September 2019. From January 2018 until March 2019, he was the President and Chief Financial Officer of Liquidia Technologies Inc., a clinical biopharmaceutical company. Mr. Gordon served as Executive Vice President and Chief Operating Officer of Quintiles Transnational Holdings Inc., or Quintiles, a research, clinical trial and pharmaceutical consulting company, from October 2015 until its merger with IMS Health Holdings, Inc. (forming IQVIA Holdings, Inc.) in October 2016. Prior to that, he was the Executive Vice President and Chief Financial Officer of Quintiles from July 2010 until December 2015. Mr. Gordon served as Executive Vice President and Chief Financial Officer of Teleflex Incorporated, a medical device company, from March 2007 until January 2010. Mr. Gordon held various senior corporate development positions at Teleflex Incorporated from 1997 to 2007. From 1992 to 1997, he held various senior positions, including Chief Financial Officer at Package Machinery Company. From 1984 to 1992, he held senior manager and other various finance positions at KPMG LLP. Mr. Gordon holds a Bachelor of Science degree in Accounting from the University of Connecticut.

What is the salary of Kevin Gordon?

As the Independent Director of Progyny Inc, the total compensation of Kevin Gordon at Progyny Inc is $281,940. There are 7 executives at Progyny Inc getting paid more, with David Schlanger having the highest compensation of $4,964,200.

How old is Kevin Gordon?

Kevin Gordon is 57, he's been the Independent Director of Progyny Inc since 2019. There are 6 older and 10 younger executives at Progyny Inc. The oldest executive at Progyny Inc is Norman Payson, 72, who is the Independent Director.

Insiders trading at Progyny Inc

Over the last 5 years, insiders at Progyny Inc have traded over $949,717,514 worth of Progyny Inc stock and bought 76,923 units worth $999,999 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Plc Gsk et Gp A, Llcbonderman Davidcou.... On average, Progyny Inc executives and independent directors trade stock every 4 days with the average trade being worth of $2,005,422. The most recent stock trade was executed by Michael E Sturmer on 16 July 2024, trading 9,030 units of PGNY stock currently worth $270,900.

What does Progyny Inc do?

progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. the benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. progyny supports all fertility solutions to include ivf, iui, embryo banking, egg freezing, adoption and surrogacy.

Complete history of Mr. Gordon stock trades at Veracyte Inc, Teleflex, Liquidia Corp et Progyny Inc

Progyny Inc executives and stock owners

Progyny Inc executives and other stock owners filed with the SEC include:

• David Schlanger,
  Chief Executive Officer, Director
• Peter Anevski,
  President, Chief Operating Officer
• David J. Schlanger,
  Exec. Chairman
• Peter Anevski,
  Chief Exec. Officer
• Mark S. Livingston,
  Chief Financial Officer
• Jennifer Bealer,
  Exec. VP, Gen. Counsel & Sec.
• Jeffrey Park,
  Independent Director
• Cheryl Scott,
  Independent Director
• Kevin Gordon,
  Independent Director
• Beth Seidenberg,
  Independent Chairman of the Board of Directors
• Norman Payson,
  Independent Director
• Frederick Cohen,
  Independent Director
• Roger Holstein,
  Director
• Malissia Clinton,
  Director
• Lisa Greenbaum,
  Executive Vice President, Chief Client Officer
• Jennifer Bealer,
  Executive Vice President, General Counsel
• Mark Livingston,
  Chief Financial Officer, Principal Accounting Officer
• Julie Stadlbauer,
  Exec. VP of Strategic Sales & Partnerships
• Michael Sturmer,
  Pres
• Cassandra Pratt,
  Sr. VP of People
• Risa Fisher,
  Exec. VP of Marketing & Communication
• James Hart,
  VP of Investor Relations
• Fred E Cohen,
  Director
• Xiii Associates, Llc Kpcb,
  10% owner
• Karin Ajmani,
  EVP, Chief of Strategic Dev.
• Perkins Caufield & Byers Xi...,
  
• Plc Gsk,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Lloyd H Dean,
  Director
• Gp A, Llcbonderman Davidcou...,
  
• Allison Swartz,
  EVP, GC
• Michael E Sturmer,
  PRESIDENT